NCT05770401

Internet-Behavioral Cough Suppression Therapy

Completed NA Results posted Last updated 5 June 2025

What this trial tests

NA trial testing Internet-Behavioral Cough Suppression Therapy in Cough in 39 participants. Completed in 1 July 2024.

Timeline

1 July 2023

Primary endpoint
1 July 2024

1 July 2024

Quick facts

Lead sponsor	University of Montana
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	39
Start date	1 July 2023
Primary completion	1 July 2024
Estimated completion	1 July 2024
Sites	1 location across United States

Drugs / interventions tested

• Internet-Behavioral Cough Suppression Therapy
• Sham Treatment — full drug profile →

Conditions studied

• Cough — all drugs for Cough →
• Chronic Disease — all drugs for Chronic Disease →

Sponsor

University of Montana

Who can join

18 and older, any sex, with Cough or Chronic Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Leicester Cough Questionnaire Primary · Pre-treatment, one-week post-treatment, one-month post-treatment

Cough-related quality of life will be measured with the Leicester Cough Questionnaire (LCQ), a valid, reliable, and repeatable measure of cough-related quality of life. The LCQ is a 19-item questionnaire containing physical, psychological, and social domains. Scores for the LCQ include mean scores for each domain (ranging from 1 to 7) and a total score calculated as the sum of the domain scores (ranging from 3 to 21). A higher score indicates better quality of life. A change in 1.3 is considered clinically significant. The LCQ total score was the primary outcome measure in this study.

Pre-intervention

Group	Value	95% CI
Internet-Behavioral Cough Suppression Therapy	9.04	± 7.32
Sham Treatment	8.86	± 7.6

One-week post-treatment

Group	Value	95% CI
Internet-Behavioral Cough Suppression Therapy	12.78	± 12.89
Sham Treatment	9.44	± 12.27

one-month post-treatment

Group	Value	95% CI
Internet-Behavioral Cough Suppression Therapy	13.04	± 4.31
Sham Treatment	9.70	± 18.38

Cough Severity Visual Analog Scale Secondary · Pre-intervention, one-week post-treatment, one-month post-treatment

Cough Severity Visual Analog Scale (VAS) is a 100-millimeter line with anchors of 0 "no problem" and 100 "worst possible problem" where participants place a mark to represent the severity of their current cough problem. A reduction of at least 30-millimeters is considered clinically meaningful for the Cough Severity VAS.

Pre-intervention

Group	Value	95% CI
Internet-Behavioral Cough Suppression Therapy	49	± 15.97
Sham Treatment	49.08	± 22.39

One-week post-treatment

Group	Value	95% CI
Internet-Behavioral Cough Suppression Therapy	33.94	± 21.32
Sham Treatment	50.08	± 22.39

One-month post-treatment

Group	Value	95% CI
Internet-Behavioral Cough Suppression Therapy	44.18	± 22.85
Sham Treatment	56.42	± 23.74

Sponsor's own description

The goal of this randomized, placebo-controlled, clinical trial is to develop and test the efficacy of an Internet-based behavioral intervention for refractory chronic cough. The main questions it aims to answer are:

* What are the best recruitment pathways to find people living with refractory chronic cough in Montana?
* Is Internet-Behavioral Cough Suppression Therapy (iBCST) efficacious?
* Do iBCST participants find it satisfactory?
* Is using Hyfe research app to monitor cough frequency feasible in rural areas?

Participants will complete iBCST or a placebo treatment virtually. Some participants will take part in qualitative interviews and use Hyfe research app for ambulatory cough frequency monitoring.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.